The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma

Cancer

Volumn 107, Issue 5, 2006, Pages 967-974

  Malaisrie, S Chris ^a,b   Hofstetter, Wayne L ^a   Correa, Arlene M ^a   Ajani, Jaffer A ^a   Komaki, Ritsuko R ^a   Rice, David C ^a   Vaporciyan, Ara A ^a   Walsh, Garrett L ^a   Roth, Jack A ^a   Wu, Tsung T ^a   Swisher, Stephen G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Esophageal cancer; Induction therapy; Neoadjuvant; Preoperative; Tumor response

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; ENTERIC FEEDING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; JEJUNOSTOMY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33747888041     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22077     Document Type: Review

References (18)

1. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984.
2. Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Arch Surg. 2004;139:532-539.
3. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-385.
4. Swisher SG, Holmes EC, Hunt KK, et al. The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg. 1996;131:819-825.
5. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727-1733.
6. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
7. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165-2174.
8. Donington JS, Miller DL, Allen MS, et al. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;24:631-637.
9. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
10. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241:810-820.
11. Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus and gastroesophageal junction. Cancer. 2001;92:279-286.
12. Ajani JA, Walsh GL, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus and gastroesophageal junction. Cancer. 2004;100:2347-2354.
13. Swisher SG, Wynn P Putnam JB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175-183.
14. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118-1123.
15. Harpole DH Jr., Moore MB, Herndon JE, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7:562-569.
16. Bains MS, Stojadinovic A, Minsky B, et al. A Phase II trial of preoperative combined modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg. 2002;124:270-277.
17. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2003;9:251-260.
18. Lamont EB, Hayreh D, Pickett KE, et al. Is patient travel distance associated with survival on Phase II clinical trials in oncology? J Natl Cancer Inst. 2003;95:1370-1375.